AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04888013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Positive Birth Environment
Description: The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
Study NCT04888013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Birth Environment
Description: The intent is to surround the woman and her caregivers with specific types of auditory, visual, and tactile stim uli. One key feature of the ambient room is what is missing-the standard hospital bed. As an alternative, a portable double-sized mattress with several large pillows is set up in a corner of the room. The intent is to allow the woman freedom in positioning and to permit close contact with support people, and to limit the routine use of continuous elec tronic fetal heart rate monitoring and other technologies during normal labor. Lighting is dimmed. A wide variety of music selections are also available.
Study NCT05329064 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BNT162b2 Pfizer-BioNTech/Comirnaty
Description: The study will use 10mcg of BNT162b2 (Pfizer-BioNTech/Comirnaty®) for each dose.~Two doses will be given at 2 months apart between doses.
Study NCT05448391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Study NCT06439303 — intervention group
Intervention type: DRUG
Intervention: Cytisine 1,5 mg
Description: Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious
Study NCT06152549 — intervention group
Intervention type: BEHAVIORAL
Intervention: Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge
Description: The first group (N=250) will receive the Maltreatment and Abuse Chronology of Exposure (MACE) scale first, to assess early life adversity, followed by the standardized test questions. A POMS will be administered before each challenge.
Study NCT06152549 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standardized Maths and Verbal Questions such as the ones used in SATs
Description: The second group (N=250) will be presented with the standardized test questions (Math/Verbal) to assess their stress level, measured through POMS, followed by the Maltreatment and Abuse Chronology of Exposure (MACE) scale.
Study NCT06152549 — intervention group
Intervention type: BEHAVIORAL
Intervention: Chronology of Perceived Discrimination Scale (CPDS)
Description: The group will also receive the Chronology of Perceived Discrimination Scale (CPDS) to assess type and timing of perceived discrimination during the first 18 years of life. A POMS will be administered before and after the intervention/challenge.
Study NCT06152549 — intervention group
Intervention type: BEHAVIORAL
Intervention: International Personality Item Pool (IPIP-NEO)
Description: Participants in both groups will be presented with the abbreviated version of the IPIP-NEO a personality questionnaire that provides ratings on the Five Factor Personality Model. The research team sees this task as non-stressful and even potentially soothing and envisions that it will help to restore an individual's mood before taking the next stressful test and again at the completion of the online session.
Study NCT05416736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The bladder stimulation technique
Description: The bladder stimulation technique consists of two consecutive maneuvers. In the first maneuver, the bladder is stimulated by tapping the suprapubic region for 30 seconds at a frequency of 100 touches per minute. In the second maneuver, circular massage is applied to the paravertebral region for 30 seconds. The two stimulation maneuvers will be repeated alternately for 3 minutes (180 seconds) until micturition begins. Maneuvers will be performed by the researcher. Infants in both groups will be held under the armpit by a parent, male infants will be held in the drooping legs, and female infants will be held in the hip flexion position.
Study NCT05416736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steril urine bag
Description: Steril urine bag are attached to the genital area to collect urine samples
Study NCT05842330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concerta
Description: Dosages of Concerta® will be defined according to the Swiss Compendium (from 18 to 72 mg/d).~The psychiatrist will start with the smallest dosage (18 mg) and will adapt it on a weekly basis or on need, depending on tolerance (side effects measured at each visit), clinical response (subjective improvement felt by the patient in terms of attention, impulsivity, and hyperactivity), and according to the observations made by the professionals or patient's entourage in term of attention, impulsivity, hyperactivity, and for this project, behavioral problems. In general, the dose can be increased in 18 mg at weekly intervals.~The treatment will be monitored weekly the first month, and then monthly, except for side effects which will be monitored daily in prison and every two weeks after release.
Study NCT05842330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be strictly identical (same packaging, size no. 2 and color according to dosage, with no label).~Procedure for adjustment of dosage will be the same as in the Concerta arm.
Study NCT06157099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Given PO
Study NCT06157099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given orally (PO)
Study NCT06157099 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06157099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06157099 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06157099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06157099 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06017349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive glucose meter
Description: Blood glucose levels were measured while fasting, after breakfast, and after lunch，Place your index finger into the non-invasive blood glucose meter and wait for the instrument to display the reading.
Study NCT06195410 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: kangaroo care application
Description: In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
Study NCT06195410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kangaroo care application
Description: In the study, the mother applied kangaroo care to her premature baby for 65 minutes, and after a 24-72 hour washout period, the father applied kangaroo care for 65 minutes.
Study NCT04230824 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-workout plus and Protein recovery plus
Description: products consumed prior and after exercise
Study NCT04230824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo product consumed prior and after exercise
Study NCT04230824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 6-week resistance training program
Description: participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
Study NCT04230824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-week resistance training program
Description: participants will complete a moderate-intensity warm-up, a full-body resistance training workout (2 x per week) and an interval training session (1 x per week)
Study NCT06017349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EKF analyzer
Description: Blood glucose levels were measured while fasting, after breakfast, and after lunch，After collecting venous blood and separating plasma, blood glucose detection is performed using the EKF analyzer with the hexokinase method.
Study NCT06017349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accu-Chek Guide
Description: Blood glucose levels were measured while fasting, after breakfast, and after lunch，Use Accu-Chek Guide blood glucose meter to prick the finger and obtain blood for glucose measurement
Study NCT05426941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Imagery
Description: Up to 30 participants will be randomized to receive 8 weekly Music Imagery sessions over 8-12 weeks.
Study NCT05426941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: Up to 15 participants will be randomized to independent music listening.
Study NCT06353880 — intervention group
Intervention type: OTHER
Intervention: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition.
Description: Participants will be categorized into three groups based on BMI and the presence of pudendal fat deposition. Sperm quality parameters, including count, motility, and morphology, will be assessed through semen analysis. Additionally, hormonal profiles related to reproductive health will be evaluated.
Study NCT05095987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy
Description: Laparoscopic Appendectomy for acute uncomplicated appendicitis in children
Study NCT04698733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BEST™ HVPC microcurrent electrical stimulation Pro-Sport Ultra® device
Description: Participants will receive two (2) 20-minute treatments a week on nonconsecutive days for 6 weeks in the clinic. At the end of 6 weeks, participants will have a 6-week pause in treatment.~Active Avazzia PRO-Sport Ultra® medical device, BEST™ HVPC microcurrent electrical stimulation, FDA cleared for pain relief
Study NCT05505032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Determination of FiO2 threshold value as an indicator of hyperoxemia in anesthesia stages.
Study NCT05505032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Root Radical 7
Description: We use it to measure the oxygen reserve index (ORi).
Study NCT04886986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-J591
Description: 30 - 40 KBq/kg (dose-escalation) every 8 weeks, for up to 2 cycles. Administered together with 177Lu-PSMA-I\&T. Intravenous administration.
Study NCT04886986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T
Description: 6.8 GBq (fixed dose) every 8 weeks, for up to 2 cycles. Administered together with 225Ac-J591. Intravenous administration.
Study NCT04886986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: \[185 ±74 MBq or 5 ±2 mCi\] intravenous during screening, 12 weeks, 24 weeks. Imaging agent for PSMA PET/CT.
Study NCT06471374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian rhythm assessment
Description: Participants will arrive approximately 8 hours before participant's scheduled bedtime to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 66 hours (2.75 days). Upon awakening in the morning, participants will start a routine of up to 39 hours of wakefulness, under bedrest conditions. Saliva will be sampled frequently and blood will be drawn 3 times. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will be provided scheduled bathroom breaks when participants will use a commode next to the bed. Outside these scheduled bathroom breaks, participants will be provided a bedpan to use to go to the bathroom. At the end of the research procedures for Visit 4 participants will be given a recovery sleep opportunity and be discharged from the lab in the morning near participant's typical waketime.
Study NCT06471374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light sensitivity assessment
Description: Participants will arrive in the afternoon to practice ability to think testing and a 9-hour sleep study. Participants will live in the laboratory for approximately 48 hours (2 days). Upon awakening in the morning, participants will be exposed to dim candlelight and then later in the day alternating intensities of dim and room light when we keep participants awake for up to 23 hours (We will ask participants to remain in bed seated for \~12.5 hours). Saliva will be sampled frequently. Reaction time, ability to think, and subjective rating tests will be performed frequently. Participants will then have a second 9-hour sleep opportunity.
Study NCT05880511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure used to relieve chronic pain and promote short-term changes. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. 2000 pulses will be delivered at 10 Hz stimulation. Stimulation will be delivered at 80% of the resting motor threshold obtained from the right APB muscle. The delivery of rTMS requires \~ 11.5 minutes in total.
Study NCT06157099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05880511 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Augmented Reality Sensorimotor Training
Description: Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
Study NCT05880511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Sensorimotor Training
Description: Sensorimotor training is a non-invasive, non-painful procedure using augmented reality to present virtual objects which cue motor action. Augmented reality allows us to project virtual objects overlaid on the user's actual environment. The sensorimotor training task involves making movements with the head and neck such that a target crosshair presented in the centre of the glasses is moved to a virtual target that is presented in the user's environment. Participants will perform 20 minutes of sensorimotor training. The goal of augmented reality sensorimotor training is to promote goal directed actions using the head and neck.
Study NCT05880511 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: Sham repetitive transcranial magnetic stimulation (rTMS) is a non-invasive, non-painful procedure. The abductor pollicis brevis (APB) muscle of the left motor cortex will be targeted using neuronavigation software. During the sham, participants will hear and experience the clicking from the device but will not be provided with any stimulation. The delivery of sham rTMS requires \~ 11.5 minutes in total.
Study NCT06582030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Ancillary studies
Study NCT06492226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKF-INS(A)
Description: Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
Study NCT06492226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-NovoRapid®
Description: Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
Study NCT06582030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the chronically relapsing brain disease vignette
Study NCT06582030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the brain disease vignette
Study NCT06582030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the disease vignette
Study NCT06582030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the illness vignette
Study NCT06582030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the disorder vignette
Study NCT06582030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: View the problem vignette
Study NCT06582030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Attend a SAS workshop
Study NCT06581913 — intervention group
Intervention type: OTHER
Intervention: Behavioral assessment
Description: Eating Awareness, Acceptance of Food Cravings, Healthy Life Awareness Health Perception
Study NCT06582485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCM012 solution 2 mg/mL
Description: 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
Study NCT06582485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.
Study NCT05081986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation
Study NCT05081986 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Single-pulse transcranial magnetic stimulation and theta-burst stimulation
Study NCT05081986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine 100mg
Study NCT05081986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo capsule matched to cycloserine capsule
Study NCT05096650 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesotherapy of platelet rich plasma and platelet poor plasma
Description: Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
Study NCT05096650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesotherapy of platelet rich plasma and platelet poor plasma
Description: Each case will receive 3 sessions of injection therapies with one month interval. Each case will receive platelet rich plasma therapy on one side of the face. The other side of the face was treated with platelet poor plasma.
Study NCT05976165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Testing
Description: Subjects drink a small carbohydrate solution, and then provide a breath sample every 15 minutes for one hour, and then every 30 minutes for the next two hours
Study NCT06492226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-NovoLog®
Description: Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
Study NCT05867992 — intervention group
Intervention type: OTHER
Intervention: Type of trauma
Description: Patients in case group have the severe traumatic brain injury, while patients in control group have the traumatic bone fracture without brain injury.
Study NCT06288685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous A1 pulley release
Description: Treatment trigger finger by release A1 pulley by percutaneous procedure
Study NCT06288685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous A1 pulley release
Description: Treatment trigger finger by release A1 pulley by percutaneous procedure
Study NCT06288685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone 40mg/ml 1 ml injection concomitant percutaneous A1 pulley release
Study NCT05258201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strain-counterstrain
Description: Strain-counterstrain is also used for manual Trigger Point processing. This involves identifying active TRP and then applying pressure until a ridiculous reaction occurs. The area is then positioned to reduce tension in the injured muscle and later reduce tripod pain. When the pain subsides, the tissues that are most stressed feel relaxed and there is a local decrease in the ground
Study NCT05258201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle Energy Technique is a common way to achieve muscle tension release (stop) before stretching other's adductor muscles
Study NCT05758857 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Guidelines-based physical activity
Description: Through a combination of exercise trainer-led in-person and virtual sessions, as well as counselling for independent aerobic exercise, participants will be guided to achieve 150 weekly minutes of moderate-intensity aerobic activity and twice weekly whole-body muscle strengthening.